Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.
Lancet Oncol
; 19(8): 1126-1134, 2018 08.
Article
em En
| MEDLINE
| ID: mdl-30026002
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ftalazinas
/
Piperazinas
/
Qualidade de Vida
/
Carcinoma Epitelial do Ovário
/
Recidiva Local de Neoplasia
/
Antineoplásicos
Tipo de estudo:
Clinical_trials
/
Diagnostic_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article